Abstract
EMPA-REG OUTCOME as first cardiovascular outcome trial demonstrated on a cohort of patients with type 2 diabetes mellitus and present macrovascular complications significant reduction of the cardiovascular and all-cause mortality and has also favorable effect on the risk of influencing the development and progression of diabetic kidney disease. Number of questions were formulated towards the elucidation of mechanisms explaining how could empagliflozin achieve beneficial effects on cardiovascular and renal predefined endpoints in this study.
Currently we do not have a clear answer, however, a lot of scientific hypothesis were formulated that should be tested. Beside a number of implications for future basic research studies have also stimulate debate about changing the status of empagliflozin in the algorithm of the pharmacotherapy in patients with type 2 diabetes.